for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AnaptysBio Inc

ANAB.OQ

Latest Trade

17.43USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

10.00

 - 

52.16

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
17.43
Open
--
Volume
--
3M AVG Volume
6.47
Today's High
--
Today's Low
--
52 Week High
52.16
52 Week Low
10.00
Shares Out (MIL)
27.30
Market Cap (MIL)
475.90
Forward P/E
-8.44
Dividend (Yield %)
--

Next Event

Q3 2020 AnaptysBio Inc Earnings Release

Latest Developments

More

Anaptysbio Announces Second Quarter 2020 Financial Results And Provides Pipeline Updates

AnaptysBio Reports Interim Top-Line Data From Phase 2 Clinical Trial Of Etokimab In Chronic Rhinosinusitis

Anaptysbio Expands Executive Leadership Team

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About AnaptysBio Inc

AnaptysBio, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product pipeline includes ANB020 and ANB019, which are being developed to treat severe inflammatory disorders with unmet medical need. The Company's ANB020 product candidate is an antibody that inhibits the activity of interleukin-33, and is used for the treatment of severe adult asthma and severe adult peanut allergy. In addition, the Company is engaged in developing its ANB019 product candidate, an antibody that inhibits the interleukin-36 receptor, for the treatment of rare inflammatory diseases called generalized pustular psoriasis (GPP) and palmoplantar pustular psoriasis (PPP).

Industry

Biotechnology & Drugs

Contact Info

10421 Pacific Center Ct Ste 200

SAN DIEGO, CA

92121-4339

United States

+1.858.3626295

https://www.anaptysbio.com/

Executive Leadership

James N. Topper

Independent Chairman of the Board

Hamza Suria

President, Chief Executive Officer, Director

Dennis M. Mulroy

Chief Financial Officer

Eric Joseph Loumeau

Chief Operating Officer, General Counsel

Paul F. Lizzul

Chief Medical Officer

Key Stats

3.00 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2017

-1.520

2018

-2.500

2019

-3.600

2020(E)

-2.110
Price To Earnings (TTM)
--
Price To Sales (TTM)
26.44
Price To Book (MRQ)
1.25
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-19.52
Return on Equity (TTM)
-18.39

Latest News

Latest News

BRIEF-Anaptysbio Announces Orphan Drug Designation Of Imsidolimab For Treatment Of Generalized Pustular Psoriasis

* ANAPTYSBIO ANNOUNCES ORPHAN DRUG DESIGNATION OF IMSIDOLIMAB FOR TREATMENT OF GENERALIZED PUSTULAR PSORIASIS

BRIEF-AnaptysBio Reports Q4 Net Loss Per Common Share $0.75

* ANAPTYSBIO ANNOUNCES FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES PIPELINE UPDATES

BRIEF-Anaptysbio Qtrly Loss Per Share $0.63

* ANAPTYSBIO ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES PIPELINE UPDATES

BRIEF-Anaptysbio Announces Positive Top-Line Proof-Of-Concept Data For ANB020 In Moderate-To-Severe Baseline Adult Peanut Allergy Patients

* ANAPTYSBIO ANNOUNCES POSITIVE TOP-LINE PROOF-OF-CONCEPT DATA FOR ANB020 IN MODERATE-TO-SEVERE BASELINE ADULT PEANUT ALLERGY PATIENTS

BRIEF-AnaptysBio Qtrly ‍Loss Per Share $0.30

* ANAPTYSBIO ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND 2018 PIPELINE MILESTONES

BRIEF-Anaptysbio qtrly loss per share $0.45

* Anaptysbio announces third quarter 2017 financial results and provides pipeline updates

BRIEF-AnaptysBio reports positive ANB019 top-line phase 1 clinical trial results

* Anaptysbio reports positive anb019 top-line phase 1 clinical trial results

BRIEF-AnaptysBio prices public offering of 3 mln shares at $68.50 per share

* Says public offering of 3.00 million common shares priced at $68.50per share Source text for Eikon: Further company coverage:

BRIEF-AnaptysBio reports positive data from phase 2A clinical trial of ANB020 in atopic dermatitis

* AnaptysBio reports positive topline proof-of-concept data from phase 2A clinical trial of ANB020 in atopic dermatitis

BRIEF-‍adage Capital reports a 6.05 percent passive stake in AnaptysBio

* Adage Capital Partners GP reports a 6.05 percent passive stake in AnaptysBio Inc as of September 22 - SEC filing Source text: (http://bit.ly/2yTdILI) Further company coverage:

BRIEF-AnaptysBio reports about 19 pct rise in Q2 revenue

* AnaptysBio announces second quarter 2017 financial results and provides pipeline updates

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up